BETA DRUGS LIMITED
BETA · General/Diversified · NSE
₹1,328
Current Market Price
Fair Value (DCF)
₹939
Margin of Safety
-29.3%
Updated 1d ago
YieldIQ Score
28/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
55%
ROE
—
Debt/Equity
0.66
WACC
11.1%
Market Cap
₹1,341 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
19.1%
Return on capital employed
EV / EBITDA
18.5×
Enterprise multiple
Debt / EBITDA
1.9×
Leverage vs earnings
Interest Coverage
9.5×
EBIT covers interest
Current Ratio
3.22×
Short-term liquidity
Asset Turnover
0.83×
Revenue per ₹ of assets
Revenue CAGR (3Y)
25.4%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,328.3
Bear case
₹570.9
MoS -132.7%
Base case
₹938.88
MoS -41.5%
Bull case
₹1,173.49
MoS -13.2%
Ratio Trends
BETA · last 4 annual periods
ROE
21.5%
ROCE
22.7%
Operating Margin
—
Debt / Equity
0.70×
PE
—
EV / EBITDA
—
Historical Financials
BETA · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹184 Cr | ₹227 Cr | ₹296 Cr | ₹362 Cr | +25.4% |
| EBITDA | ₹43.3 Cr | ₹53.7 Cr | ₹61.2 Cr | ₹76.2 Cr | +20.7% |
| EBIT | — | — | — | — | — |
| PAT | ₹24.8 Cr | ₹30.7 Cr | ₹36.4 Cr | ₹42.4 Cr | +19.5% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹29.6 Cr | ₹23.4 Cr | ₹30.9 Cr | ₹36.1 Cr | +6.9% |
| CapEx | ₹-19.4 Cr | ₹-18.2 Cr | ₹-11.6 Cr | ₹-36.9 Cr | — |
| FCF | ₹10.2 Cr | ₹5.2 Cr | ₹19.3 Cr | ₹-0.7 Cr | — |
| Total Assets | ₹158 Cr | ₹198 Cr | ₹254 Cr | ₹436 Cr | +40.3% |
| Total Debt | ₹20.6 Cr | ₹20.3 Cr | ₹14.7 Cr | ₹138 Cr | +88.5% |
| Shareholders' Equity | ₹92.3 Cr | ₹123 Cr | ₹157 Cr | ₹197 Cr | +28.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BETA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| VENUSREM VENUSREM | — | — | Pending | 8.1% | — |
| SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
| SAKAR SAKAR | — | — | Pending | 6.1% | — |
| JAGSNPHARM JAGSONPAL PHARMACEUTICALS | -6.1% | 61 | Near Fair Value | 23.1% | — |
| AMRUTANJAN AMRUTANJAN | — | — | Pending | 15.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for BETA in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. BETA DRUGS LIMITED (BETA.NS) trades at 1328.30 vs a model fair value of 938.88, a gap of -29.3%. Piotroski F-score: 6/9. Moat label: Mode...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BETA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BETA →
Compare
Head-to-head with peers
Compare BETA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BETANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.